Clinical Trial Update: An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma [Phase 3]

View source ↗

Summary

This Phase 3 open-label trial compares glofitamab to the Pola-R-CHP regimen in previously untreated Large B-cell lymphoma; the study is currently active and not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large B-cell Lymphoma

Drugs mentioned

• Adriamycin (doxorubicin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Columvi (glofitamab)
• Deltasone (prednisone)
• Polivy (polatuzumab vedotin)
• Rituxan (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Large B-Cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING